Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Kodiak Sciences Inc KOD

Healthcare Biotechnology
Kodiak Sciences Inc. is a biopharmaceutical company. The Company has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) Platform, for retinal medicines. Its ABC Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies. Its lead investigational medicine, tarcocimab, is a novel anti-vascular endothelial growth factor (anti... see more

Recent & Breaking News (NDAQ:KOD)

Kodiak Sciences Announces Upcoming Presentation of Additional KSI-301 Phase 1b Clinical Study Data at Angiogenesis, Exudation, and Degeneration 2020 Meeting

PR Newswire February 5, 2020

Kodiak Sciences to Present at 38th Annual J.P. Morgan Healthcare Conference

PR Newswire January 8, 2020

Kodiak Sciences Appoints Taiyin Yang, Ph.D., to Board of Directors

PR Newswire December 19, 2019

Kodiak Sciences Announces Pricing of $276.0 Million Public Offering of Common Stock

PR Newswire December 3, 2019

Kodiak Sciences Announces Proposed Offering of Common Stock

PR Newswire December 2, 2019

Kodiak Sciences to Present at the Evercore ISI HealthCONx Conference

PR Newswire December 2, 2019

Kodiak Sciences Announces Sale of Future Royalties on KSI-301 for $225 Million to Baker Bros. Advisors

PR Newswire December 2, 2019

Kodiak Sciences Announces Third Quarter 2019 Financial Results and Recent Business Highlights

PR Newswire November 12, 2019

Kodiak Sciences to Report Third Quarter 2019 Results and Host Business Highlights Webcast on November 12, 2019

PR Newswire November 8, 2019

Kodiak Sciences Announces Safety, Efficacy and Durability Data from Ongoing Phase 1b Study of KSI-301 in Patients with Wet Age-Related Macular Degeneration, Diabetic Macular Edema and Retinal Vein Occlusion at the American Academy of Ophthalmology Annual Meeting Retina Subspecialty Day

PR Newswire October 11, 2019

Kodiak Sciences to Host R&D Day on October 14 in San Francisco to Highlight Recent Clinical Progress and Development Planning for KSI-301

PR Newswire October 11, 2019

Kodiak Sciences Treats First Patients in DAZZLE Pivotal Study of KSI-301 in Wet Age-Related Macular Degeneration

PR Newswire October 10, 2019

Kodiak Sciences Announces Upcoming Presentation of Durability Data from Clinical Development Program of KSI-301 in Wet AMD, DME, and RVO at American Academy of Ophthalmology 2019 Annual Meeting

PR Newswire October 7, 2019

Kodiak Sciences Announces Emerging Durability Data from Ongoing Phase 1b Study of KSI-301 in Wet AMD Patients at The Retina Society Annual Meeting

PR Newswire September 15, 2019

Kodiak Sciences to Release Durability Data from Clinical Development Program of KSI-301 for wet AMD at The Retina Society Annual Meeting

PR Newswire September 12, 2019

Kodiak Sciences to Present at the Morgan Stanley Global Healthcare Conference

PR Newswire September 6, 2019

Kodiak Sciences Announces Upcoming Presentations at EURETINA Meeting

PR Newswire September 4, 2019

Kodiak Sciences Announces Second Quarter 2019 Financial Results and Recent Business Highlights

PR Newswire August 14, 2019

Kodiak Sciences to Present at Wedbush PacGrow Healthcare Conference

PR Newswire August 8, 2019

Kodiak Sciences Announces Positive Interim Data from Ongoing Phase 1b Clinical Study of KSI-301, a Novel Anti-VEGF Antibody Biopolymer Conjugate for Treatment of Wet AMD, Diabetic Eye Disease, and Retinal Vein Occlusion, at the American Society of Retina Specialists 2019 Annual Meeting

PR Newswire July 27, 2019